TRPC5 and breast carcinoma: The human oestrogen receptor positive (ER+) MCF-7 breast cancer cell line feature high levels of TRPC5 expression making them resistant to doxorubicin cytotoxic effect [32], and TRPC5 silencing can increase sensitivity to doxorubicin by reducing (MDR)ATPase 1 expression.